Executive Summary
Left atrial reservoir strain measured one month after MitraClip independently predicts survival in functional MR, giving operators an early, actionable read on who is actually reverse-remodeling — a 128-patient single-center analysis in JACC: Asia found ≥15% LARS improvement tracked with lower death and heart failure hospitalization, independent of residual MR or transmitral gradient. A Brazilian multicenter propensity analysis reports no significant procedural or mortality differences between bicuspid and tricuspid TAVI, though small BAV numbers (n=90 matched) and in-hospital-only endpoints limit what this settles. The connective tissue across today's coverage is lifetime management: a European Cardiology commentary argues alignment, coronary protection, and redo planning are now mandatory at the index TAVI, tightening the case for pre-procedural CT rigor and complicating the "any valve will do" posture in patients under 75.
- MitraClip responders are identifiable within 30 days by LARS delta, not by residual MR grade, in the Hiroshima FMR cohort.
- Bicuspid TAVI showed no propensity-matched excess in mortality, stroke, or vascular complications versus tricuspid AS in the Brazilian registry — in-hospital endpoints only.
- A Chinese team published the NCPI-plus technique in JACC: Case Reports for pure AR with enlarged LVOT, an anatomy still without a dedicated device.
- Bicaval valve implantation delivered symptomatic relief in a pacemaker-dependent patient with torrential TR in a Journal of Cardiology Cases report, without RV recovery.
- ACC flagged persistent leadership gaps in structural heart trial authorship, a durable underrepresentation problem the field has not fixed.
What to watch: Medtronic's fiscal Q1 earnings on September 1, where structural heart segment commentary will land against a -7% six-month stock trajectory and a leadership departure to Versa Vascular.
Aortic Valve (TAVR/TAVI)
Bicuspid TAVI outcomes in a middle-income setting look similar to tricuspid — but the sample is small and the follow-up is short. The Brazilian multicenter registry matched 90 BAV to 243 TAV patients across 25 centers (2009-2021) and found no significant differences in in-hospital mortality (7% vs 3%, p=0.21), stroke (2% vs 0.4%), or major bleeding. In-hospital endpoints in a retrospective registry are the softest possible durability read, and a numerical mortality doubling in BAV would matter if the study were powered for it. An accompanying editorial in Arquivos Brasileiros de Cardiologia asks the right question: what happens next? Both ACC/AHA 2020 and ESC 2025 still treat BAV TAVI as Class IIb, and NOTION-2's 100-BAV signal (HR 3.8 for events with TAVI, p=0.07) is not erased by an in-hospital analysis. SAVR remains the guideline preference for younger BAV patients with aortopathy or heavy calcification — a recommendation this registry cannot challenge without longitudinal follow-up.
The European Cardiology commentary on lifetime management pushes commissural alignment and redo-strategy planning from "nice-to-have" to standard-of-care at the index TAVI — an appropriate reframing given THV explant mortality still runs 12-17%. A JACC: Case Reports piece on STJ-constrained anatomy reinforces that CT-based pre-planning is where the procedure is won or lost.
Mitral Valve (MitraClip, PASCAL, TMVR)
[NOTABLE] Left atrial reservoir strain is the response biomarker MitraClip has needed — with the caveats that come with n=128 and a single center. The Hiroshima University cohort (n=128, median age 80, 31% atrial FMR) shows that a ≥15% relative LARS increase at one month independently predicts freedom from death and heart failure hospitalization at 14 months. The clinically important finding: residual MR grade and transmitral gradient did NOT predict LARS improvement or outcome — the predictors were absence of persistent AF, lower baseline LARS, and preserved renal function. This is a phenotyping tool, not a procedural quality metric. Limitations are the usual: retrospective, single-center, no external validation, and strain measurement reproducibility varies by lab.
The ESC 2025 formalization of atrial secondary MR as a distinct entity (preserved LVEF, annular dilation, LA enlargement) sits directly on top of this finding — 31% of the cohort was atrial subtype. ACC/AHA 2020 rates TEER for ventricular SMR as Class IIa; ESC 2025 upgraded it to Class I, LOE A, based on COAPT 5-year follow-up and RESHAPE-HF2. For atrial SMR specifically, ESC 2025 favors MV surgery plus surgical AF ablation plus LAAO (Class IIa) over TEER (Class IIb) when the patient is operable. LARS-guided selection could sharpen who gets which pathway — but only after multi-center validation.
A Kardiologia Polska letter on late atrial migration of a transcatheter mitral valve after prior valve-in-valve TAVI is a reminder that TMVR device fixation in native and post-VIV anatomy is unsolved.
Tricuspid Valve (TriClip, TTVR)
Two case reports extend the transcatheter TR toolkit at both ends of the severity spectrum. Bicaval valve implantation in a 60-year-old with torrential TR, pacemaker in situ, and intractable ascites delivered symptomatic and ascites improvement at six months — but no RV structural recovery. Heterotopic CAVI addresses venous congestion, not the tricuspid lesion itself, and belongs in the palliative column. ESC 2025 upgraded TV surgery for symptomatic severe primary TR to Class I; for a pacemaker-dependent patient with end-stage RV failure, CAVI is what remains after that window has closed.
A European Heart Journal Case Reports paper demonstrates T-TEER guided entirely by 3D intracardiac echo under local anesthesia in a 74-year-old with severe mixed secondary TR — two clips, clover technique, discharge without complication. ICE-only guidance is clinically meaningful for the frail TR population where TEE and general anesthesia carry real procedural risk. ESC 2025 made transcatheter TV treatment Class IIa, LOE A for high-risk symptomatic severe TR without severe RV dysfunction or pre-capillary pulmonary hypertension, based on TRILUMINATE Pivotal, Tri.Fr, and TRISCEND II. ACC/AHA 2020 does not address transcatheter TR therapy at all — a gap that widens with each of these procedural refinements.
Surgical vs. Transcatheter Comparisons
No head-to-head randomized data today. The Brazilian BAV TAVI registry sits against a surgical comparator the study didn't include — SAVR for BAV in this population would be the appropriate benchmark, and its absence is the study's biggest gap. A commentary in the Journal of Cardiothoracic and Vascular Anesthesia flags interpretive limits of propensity-matched SAVR-vs-TAVR comparisons in reduced-EF patients, echoing the broader concern that observational matching cannot reproduce randomization, particularly for durability-sensitive decisions. ESC 2025 age thresholds — SAVR preferred below 70, TAVI at or above 70 with suitable anatomy — push transcatheter into younger patients than ACC/AHA 2020 (SAVR preferred below 65, TAVI preferred above 80), a 5-to-10-year expansion that raises the stakes on exactly the durability questions retrospective registries cannot answer.
Device & Technology
JACC: Case Reports published the NCPI-plus technique from Junbo Ge's group at Zhongshan Hospital for TAVR in pure aortic regurgitation with enlarged LVOT (perimeter 93.7 mm in this case). The approach uses a supra-annular pivot at the noncoronary sinus and deep LVOT engagement at the left coronary sinus, with a 30-mm self-expanding valve and 16.8% oversizing — down from 22.1% with standard NCPI. Twelve-month echo showed no gradient and no AR. This is n=1, and pure AR without a dedicated device remains a niche where JenaValve's Trilogy (recently FDA-approved) holds the anatomical claim. ESC 2025 rates TAVI for AR as Class IIb for inoperable patients only; SAVR remains the standard for operable candidates regardless of anatomy. The BACTRA technique — balloon-assisted valve crossing via trans-radial access — was reported in two challenging TAVI cases (horizontal aorta, severe tortuosity) as a strategy to avoid a second femoral puncture.
Industry & Market
Medtronic's structural heart leader was appointed CEO of Versa Vascular, per MassDevice. Executive departures from Medtronic's structural business matter more than they used to, in a moment where Evolut competes head-to-head with SAPIEN 3 Ultra RESILIA and Myval has demonstrated 1-year noninferiority in LANDMARK. The ACC's report on persistent leadership gaps in structural heart trial authorship names a durable industry problem — women and underrepresented groups continue to lead a small fraction of pivotal trials, which shapes trial design and which populations get studied.
Financial Analysis
Edwards traded near $93 with a market cap of $53.6B and a forward P/E of 27.6 — pricing that Seeking Alpha flagged as leaving little room for execution error. The clinical undercurrent supporting Edwards' TAVR growth thesis — EARLY TAVR moving asymptomatic severe AS into intervention, ESC 2025 lowering the TAVI age threshold to 70 — is intact. The emergence of Myval (Meril, private), continued momentum for Boston Scientific's ACURATE platform (despite BSX's -31% six-month drop), and the DEDICATE data supporting broad transcatheter parity all point to a more contested market than the multiple suggests. Boston Scientific's six-month decline reflects specific product and pipeline concerns rather than a structural heart thesis break. Medtronic's -7% six-month move and the structural heart leadership departure invite scrutiny at the September 1 earnings call.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Close: $93.05 (-0.65% daily); 6-month: +22.64%
- Market cap: $53.6B; trailing P/E 55.7, forward P/E 27.6; beta 0.85
- 52-week range: $72.30 - $96.29
- Analyst target: $100.96 (26 analysts); consensus: buy
- Next earnings: October 29 (EPS est $0.74, revenue est $1.68B)
The pure-play structural heart name is trading near its 52-week high. EARLY TAVR tailwinds and ESC 2025's age-threshold shift support volume growth; the M-TEER franchise (PASCAL) and tricuspid (EVOQUE) round out the story. Valuation leaves little margin for a soft quarter.
Medtronic (MDT)
- Close: $90.76 (+0.09% daily); 6-month: -7.20%
- Market cap: $116.2B; trailing P/E 24.3, forward P/E 14.2; beta 0.57
- 52-week range: $73.31 - $106.33
- Analyst target: $98.44 (25 analysts); consensus: buy
- Next earnings: September 1 (EPS est $1.39, revenue est $9.55B)
Structural heart leadership departure to Versa Vascular lands ahead of earnings. Evolut FX+ needs to demonstrate share retention against SAPIEN 3 Ultra RESILIA and the Myval entry documented in LANDMARK.
Abbott (ABT)
- Close: $110.91 (+1.08% daily); 6-month: -0.25%
- Market cap: $193.2B; trailing P/E 35.4, forward P/E 18.3; beta 0.58
- 52-week range: $81.97 - $137.49
- Analyst target: $118.42 (24 analysts); consensus: buy
- Next earnings: October 14 (EPS est $1.42, revenue est $12.99B)
MitraClip and TriClip anchor Abbott's structural heart position. ESC 2025's Class I upgrade for TEER in ventricular SMR is a durable tailwind; the atrial SMR phenotype flagged in today's LARS data broadens the addressable population.
Boston Scientific (BSX)
- Close: $51.42 (+0.45% daily); 6-month: -31.19%
- Market cap: $74.5B; trailing P/E 20.7, forward P/E 15.0; beta 0.57
- 52-week range: $42.20 - $109.50
- Analyst target: $62.69 (29 analysts); consensus: buy
- Next earnings: October 28 (EPS est $0.81, revenue est $5.26B)
Six-month drawdown reflects broader pipeline and electrophysiology concerns rather than a structural heart thesis break. ACURATE neo2 remains a competitive TAVI platform in Europe.
Anteris Technologies (AVR.AX)
- Close: A$12.33 (-4.05% daily); 6-month: +58.69%
- Market cap: A$1.2B; forward P/E negative; beta 0.73
- 52-week range: A$5.20 - A$15.47
- Single-analyst target: A$13.00
DurAVR (single-piece bioengineered leaflet) sits directly in the durability debate that today's lifetime-management commentary makes central. Small-cap volatility persists.
The read across the group: consolidation of ESC 2025 into practice favors procedure-volume growth at Edwards and Abbott. JenaValve, Meril, and J Valve Technology (private) shape the competitive edge without appearing on the tape.
Clinical Trial Updates
Aortic Valve
- NCT07759427 — Using Non-Invasive Mapping To Eliminate Structural Heart Disease Ventricular Tachycardia. Status: recruiting. Phase: NA. Enrollment: 110. Sponsor: University of Warwick. VIVO-assisted mapping intervention. Last updated August 12.
No new landmark valve trial status changes today (REPAIR-MR, PRIMARY, TRILUMINATE, CLASP TR, APOLLO, TRISCEND, PARTNER, COAPT unchanged).
Social & Conference Highlights
The American College of Cardiology published on persistent leadership gaps in structural heart disease trials — women and underrepresented groups continue to lead a minority of pivotal trials, which shapes trial design, inclusion criteria, and generalizability. This is the field's slowest-moving problem.
LARS as a MitraClip response biomarker needs multi-center validation before it changes selection. The Brazilian BAV TAVI data need longer follow-up before they change anything. Medtronic's September 1 earnings will define whether the structural heart segment is holding share or ceding it to SAPIEN 3 Ultra RESILIA and the new balloon-expandable entrants.
— E. Nolan Beckett, MD